# Neonatal Jaundice Phototherapy Thresholds

For infants born at 35 weeks’ gestation or later, initiate phototherapy using the 2022 AAP hour-specific total serum bilirubin threshold matched to gestational age and bilirubin neurotoxicity risk factors, then use the bilirubin-to-threshold difference to determine discharge follow-up and escalation.

**Clinical question:** How should clinicians apply AAP 2022 bilirubin thresholds to start phototherapy and escalate care in infants born at 35 weeks or later?

Updated: 2026-09-15T21:37:18.569803+00:00

## What matters in practice
- Apply the AAP 2022 hour-specific phototherapy threshold using postnatal age, gestational age, and bilirubin neurotoxicity risk factors; treatment thresholds are higher than in the 2004 guideline. [8][14][17][18]
- Obtain and act on bilirubin measurements before discharge; the difference between the predischarge bilirubin and the applicable phototherapy threshold determines follow-up intensity. [17][18]
- Use the lower risk-factor treatment curve when albumin is low, hemolysis is present, sepsis is suspected or confirmed, or the infant is clinically unstable. [17]
- Acute bilirubin encephalopathy requires immediate exchange transfusion preparation with phototherapy started or continued during and after the procedure. [3]
- Do not use race as a bilirubin risk variable; identify hemolytic and genetic risk through clinical history and testing, including consideration of G6PD deficiency. [8][14]

## Select the AAP 2022 phototherapy threshold before treating

The guideline applies to newborns at least 35 weeks’ gestation.

Plot total serum bilirubin (TSB) against the 2022 AAP hour-specific phototherapy threshold using the infant’s exact postnatal age, gestational age, and presence or absence of bilirubin neurotoxicity risk factors. The revised AAP thresholds for both phototherapy and exchange transfusion are higher than those in the 2004 guidance. [8][14][15][17][18]

Gestational age is incorporated directly into the treatment threshold. Use the risk-factor threshold rather than the no-additional-risk-factor threshold when there is low albumin, isoimmune or other hemolytic disease, sepsis, or clinical instability. These factors increase bilirubin neurotoxicity risk and lower the treatment threshold selected for a given age and gestational age. [17]

A visible jaundice pattern should not substitute for a bilirubin value. Use transcutaneous bilirubinometry as screening when available, but obtain TSB for threshold-based treatment decisions and for an infant receiving or recently completing phototherapy. TcB after phototherapy underestimates TSB by a mean 2.4 mg/dL, with substantial variability. [6][19]
- Record postnatal age in completed hours at every threshold decision; do not use calendar day alone. [17][18]
- Use the infant’s gestational age at birth, not corrected gestational age, for the AAP treatment curves. [17][18]
- Interpret an early bilirubin rise or jaundice in the first 24 hours as a trigger to assess for hemolysis and closer surveillance rather than physiologic jaundice. [4][17]

*Variables that determine the applicable AAP 2022 treatment pathway. [17][18]*

| Decision variable | What changes | Clinical action |
| --- | --- | --- |
| Postnatal age in hours | Both phototherapy and exchange thresholds are hour-specific. [17][18] | Plot every TSB against the age-specific threshold rather than using a single bilirubin cutoff. [17][18] |
| Gestational age at birth | Lower gestational age is associated with lower treatment thresholds. [17][18] | Use the gestational-age-specific AAP curve for every infant born at least 35 weeks. [17][18] |
| Neurotoxicity risk factor | Low albumin, hemolysis, sepsis, or clinical instability moves the infant to the lower risk-factor threshold. [17] | Treat and escalate according to the risk-factor curve. [17] |
| TSB relative to threshold | The gap between predischarge bilirubin and phototherapy threshold guides follow-up timing. [17] | Arrange closer reassessment as the TSB approaches the applicable threshold. [17] |

## Identify infants who need early bilirubin assessment and hemolysis evaluation

The highest-yield branch point is early jaundice or a bilirubin trajectory suggesting excess production.

Measure bilirubin promptly when jaundice is recognized during the first 24 hours after birth. This pattern is associated with severe hyperbilirubinemia and should shift the evaluation toward isoimmune hemolysis, other hemolytic disease, bruising or cephalhematoma, and G6PD deficiency rather than routine observation. [4][17]

Review maternal antibody status and identify maternal anti-erythrocyte antibodies before discharge. If isoimmune disease or another hemolytic process is present, apply the neurotoxicity risk-factor treatment threshold and monitor the TSB trajectory closely because hemolysis can drive rapid bilirubin accumulation. [13][17]

Ask specifically about a prior sibling treated with phototherapy, gestational age of 35 to 36 weeks, poor feeding, bruising, cephalhematoma, and family ancestry or history compatible with G6PD deficiency. The 2022 AAP approach removed race as a risk factor; clinical assessment should instead identify biologically relevant risks such as G6PD deficiency and hemolysis. [4][8][14][17]
- Jaundice in the first 24 hours: obtain bilirubin measurement and evaluate for hemolysis. [4][17]
- Maternal anti-erythrocyte antibodies or suspected isoimmunization: use the neurotoxicity risk-factor threshold and anticipate possible escalation. [13][17]
- Poor feeding before discharge: obtain objective bilirubin assessment and plan follow-up according to distance from the phototherapy threshold. [17]
- Near-term birth at 35 to 36 weeks: use the lower gestational-age threshold, not a term-infant approximation. [4][17]

*Clinical findings that change bilirubin testing and threshold selection. [4][8][14][17]*

| Finding | Likely concern | Threshold or next-step consequence |
| --- | --- | --- |
| Jaundice before 24 hours | Hemolysis or other pathologic bilirubin production. [4][17] | Measure bilirubin promptly; evaluate for hemolysis and use risk-factor thresholds if hemolysis is identified. [17] |
| Maternal antibody exposure or infant hemolytic disease | Rapid bilirubin rise and neurotoxicity risk. [13][17] | Use the neurotoxicity risk-factor curve; intensify surveillance and prepare for escalation if TSB rises. [17] |
| Bruising or cephalhematoma | Increased bilirubin load from extravasated blood. [4] | Increase bilirubin surveillance and determine follow-up by the TSB-to-threshold difference. [17] |
| Possible G6PD deficiency | Hemolysis may be unrecognized and severe hyperbilirubinemia risk is increased. [4][14] | Assess clinically and test when indicated; do not use race as a substitute for risk assessment. [8][14] |

## Start intensive phototherapy when TSB reaches the applicable threshold

Phototherapy is the first-line intervention for threshold-level unconjugated hyperbilirubinemia.

When TSB meets the applicable AAP phototherapy threshold, start phototherapy rather than waiting for jaundice progression. Phototherapy lowers unconjugated bilirubin by converting it into water-soluble isomers for excretion and has markedly reduced the need for exchange transfusion. [6][24]

For severe hyperbilirubinemia or an infant approaching escalation, use intensive phototherapy with optimized irradiance. Bilirubin absorbs blue light most strongly around 460 nm; the reported effective phototherapy range is 460 to 490 nm, optimally 478 nm. An irradiance of at least 30 microwatts/cm² at 478 nm is cited for intensive treatment. [3]

Verify the actual device irradiance at the infant’s skin surface, maximize exposed skin area, and avoid assuming that a second device is equivalent to adequate delivered light dose. Overhead LED phototherapy has been associated with a faster TSB decline and shorter treatment duration than conventional compact fluorescent or halogen systems; double-light therapy is often used to increase irradiance. [3]

Maintain feeding assessment and clinical monitoring during treatment, but do not delay indicated phototherapy while addressing intake. Phototherapy is contraindicated in congenital porphyria and in infants receiving photosensitizing drugs. [24]
- Use TSB, not post-phototherapy TcB alone, to judge treatment response because TcB can underestimate serum bilirubin after treatment. [19]
- Confirm wavelength and irradiance when bilirubin is not declining as expected; inadequate light delivery is a remediable cause of apparent treatment failure. [3][24]
- Continue to plot serial TSB by age and gestational age during severe disease to determine need for continued phototherapy or repeat exchange transfusion. [3]

### When observation rather than phototherapy is appropriate

Observation is appropriate only when the measured bilirubin remains below the applicable hour-specific phototherapy threshold and the planned follow-up interval is determined by the bilirubin-to-threshold difference. Jaundice beginning on the second postnatal day and resolving within 7 to 10 days may be physiologic, but a normal transcutaneous measurement alone does not replace a TSB when treatment-level hyperbilirubinemia is suspected. [3][17]

*Operational phototherapy checks for infants who meet treatment criteria. [3][19][24]*

| Treatment element | Action | Reason to change management |
| --- | --- | --- |
| Threshold confirmation | Use TSB plotted by hour of age, gestational age, and neurotoxicity risk factors. [17][18] | Prevents treatment using an inapplicable age- or risk-independent cutoff. [17][18] |
| Light delivery | Use blue-spectrum treatment in the 460-490 nm range and verify adequate irradiance; intensive therapy is cited at at least 30 microwatts/cm² near 478 nm. [3] | Inadequate irradiance may slow TSB decline and increase need for escalation. [3][24] |
| Monitoring method | Use serial TSB during active treatment and severe disease. [3][19] | TcB after phototherapy may underestimate TSB. [19] |
| Contraindications | Avoid phototherapy in congenital porphyria or with photosensitizing drugs. [24] | Select an alternative urgent pathway, including exchange transfusion when clinically indicated. [3][24] |

## Escalate care for bilirubin near exchange level or acute bilirubin encephalopathy

Clinical neurologic signs override reassurance from a falling bilirubin concentration.

Use the AAP escalation-of-care framework when TSB approaches the exchange-transfusion threshold. The 2022 guideline added escalation-of-care risk assessment and includes separate exchange-transfusion nomograms based on postnatal age, gestational age, and neurotoxicity risk factors. [8][15][17][18]

Treat signs of acute bilirubin encephalopathy as an emergency: hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry, or recurrent apnea warrant immediate exchange transfusion, even when TSB is falling. Start phototherapy while preparing for exchange transfusion and continue it afterward. [3]

Exchange transfusion is a rescue intervention for severe hyperbilirubinemia and remains a critical procedure despite becoming uncommon in high-resource settings. It rapidly lowers bilirubin and antibody burden in severe hemolytic disease, but requires procedural expertise and carries meaningful procedural risk. [6][11]
- Do not wait for repeat bilirubin testing before mobilizing exchange-transfusion capability when acute bilirubin encephalopathy is present. [3]
- Continue serial TSB plotting after exchange transfusion to identify a need for ongoing phototherapy or repeat exchange transfusion. [3]
- In alloimmune hemolytic disease, IVIG has been used with phototherapy and exchange transfusion; reported dosing is 0.5 to 1 g/kg, but evidence that it prevents exchange transfusion remains conflicting. [13]

### IVIG is not a substitute for exchange readiness

Consider IVIG only in the narrow context of alloimmune hemolytic disease with severe hyperbilirubinemia despite phototherapy and possible exchange-transfusion need. A reported dose is 0.5 to 1 g/kg, but systematic-review concerns and conflicting clinical outcomes mean IVIG should not delay intensive phototherapy, serial TSB assessment, or exchange-transfusion preparation. [13]

*Escalation decisions for severe neonatal hyperbilirubinemia. [3][8][11][13][17]*

| Trigger | Immediate action | Do not delay |
| --- | --- | --- |
| TSB approaches AAP exchange-transfusion threshold | Enter escalation-of-care pathway and use the applicable exchange-transfusion nomogram. [8][15][17] | Intensive phototherapy and preparation for higher-level intervention. [3][17] |
| Acute bilirubin encephalopathy signs | Proceed with immediate exchange transfusion; begin or continue phototherapy. [3] | Exchange preparation while awaiting additional TSB trends. [3] |
| Alloimmune hemolytic disease with severe trajectory | Use intensive phototherapy and exchange readiness; IVIG may be considered at 0.5-1 g/kg. [13] | Definitive rescue planning because IVIG benefit is uncertain. [13] |

## Base postdischarge bilirubin follow-up on distance from the treatment threshold

Disposition is determined by the bilirubin margin, not by a categorical low-, intermediate-, or high-risk zone.

Before discharge, obtain bilirubin screening with TSB or TcB and calculate the difference between the measured bilirubin and the applicable hour-specific phototherapy threshold. The smaller this difference, the closer and earlier the follow-up bilirubin assessment should be. This replaces the earlier approach of using a predischarge risk-zone classification alone. [6][17]

Include feeding adequacy, clinical stability, gestational age, visible jaundice progression, and hemolysis risk in the discharge decision. Lower gestational age, jaundice in the first 24 hours, poor feeding, and maternal anti-erythrocyte antibodies identify infants needing more cautious surveillance. [4][17]

After phototherapy is discontinued, obtain planned follow-up assessment for rebound hyperbilirubinemia according to the AAP follow-up recommendations. Use TSB for a rebound decision when recent phototherapy makes TcB potentially inaccurate. [17][19]
- Document the exact TSB or TcB value, postnatal age in hours, gestational age, neurotoxicity risk factors, applicable phototherapy threshold, and bilirubin-to-threshold difference at discharge. [17][18]
- Arrange earlier follow-up when the predischarge bilirubin is close to the treatment threshold rather than relying on an infant’s well appearance. [17]
- Reassess promptly if jaundice progresses, feeding worsens, or clinical instability develops because these changes may alter threshold selection and urgency. [17]

*Discharge and post-phototherapy monitoring framework. [17][19]*

| Clinical setting | Required comparison | Next decision |
| --- | --- | --- |
| Predischarge assessment | Compare bilirubin with the age-, gestational age-, and risk-specific phototherapy threshold. [17][18] | Set follow-up timing by the difference between measured bilirubin and threshold. [17] |
| Infant near treatment threshold | Small bilirubin-to-threshold difference. [17] | Arrange closer bilirubin reassessment and clinical follow-up. [17] |
| After phototherapy | Assess for rebound using planned follow-up; recognize TcB underestimation after treatment. [17][19] | Use TSB when evaluating possible rebound requiring renewed treatment. [19] |

## References
1. PREDICTION OF SEVERE NEONATAL HYPERBILIRUBINEMIA ... — adc.bmj.com — https://adc.bmj.com/content/93/Suppl_2/pw336
2. Neonatal jaundice - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/672
3. Neonatal jaundice - Treatment algorithm | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/672/treatment-algorithm
4. Incidence and causes of severe neonatal hyperbilirubinemia in Canada — bmjpaedsopen.bmj.com — https://bmjpaedsopen.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY21haiI7czo1OiJyZXNpZCI7czo5OiIxNzUvNi81ODciO3M6NDoiYXRvbSI7czoyMzoiL2JtanBvLzEvMS9lMDAwMTA1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==
5. Readmission rates before and after the implementation of 2022 revised AAP clinical practice guidelines for the management of neonatal hyperbilirubinemia - a single center study | Journal of Perinatology — preview-www.nature.com — https://preview-www.nature.com/articles/s41372-025-02451-6.pdf
6. Management of Neonatal Hyperbilirubinemia | Neonatology | Paediatrics | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/management-of-neonatal-hyperbilirubinemia
7. Citrate-functionalized manganese oxide nanoparticles in neonates ≥35 weeks gestation at risk of acute bilirubin encephalopathy: a phase 1 observational trial | Pediatric Research — www.nature.com — https://www.nature.com/articles/s41390-026-05144-8
8. Neonatal jaundice: Recommendations for follow-up and treatment — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2667009723000970
9. Real‐World Outcomes of the 2022 American Academy of Pediatrics Hyperbilirubinemia Guideline - Nissimov - 2025 - Journal of Paediatrics and Child Health - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jpc.70124?af=R
10. [PDF] Implementation of the Revised American Academy of Pediatrics ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S1553725024003283
11. Blood Exchange Transfusion for Infants with Severe Neonatal Hyperbilirubinemia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0146000511000425
12. Readmission Reduction for Hyperbilirubinemia in Infants ≥ 35 Weeks Estimated Gestational Age Using a Standardized Protocol - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1553725023001599
13. Intravenous Immunoglobulin in Hemolytic Disease... : Nigerian Journal of Clinical Practice — journals.lww.com — https://journals.lww.com/njcp/fulltext/2022/25080/intravenous_immunoglobulin_in_hemolytic_disease_of.10.aspx
14. What’s Up (And Down) With the New Bilirubin Guidelines | AAP Journal Blogs | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/journal-blogs/blog/21896/What-s-Up-And-Down-With-the-New-Bilirubin
15. Bilirubin Measurement and Phototherapy Use After the AAP 2022 Newborn Hyperbilirubinemia Guideline | Pediatrics | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatrics/article/153/4/e2023063323/196871/Bilirubin-Measurement-and-Phototherapy-Use-After
16. Fewer Phototherapy Admissions After New AAP Jaundice Guideline | AAP Grand Rounds | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/aapgrandrounds/article/54/4/41/204368/Fewer-Phototherapy-Admissions-After-New-AAP
17. AAP releases updated guidance for managing neonatal hyperbilirubinemia | AAP News | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/aapnews/news/20874/AAP-releases-updated-guidance-for-managing
18. Management of Hyperbilirubinemia in the Newborn Infant 35 or ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/150/3/e2022058859
19. Transcutaneous Bilirubin After Phototherapy in Term and Preterm ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/early/2014/10/15/peds.2014-1677
20. Neonatal Jaundice | Pediatrics In Review - AAP Publications — pedsinreview.aappublications.org — http://pedsinreview.aappublications.org/lookup/doi/10.1542/pir.27-12-443
21. Neonatal Indirect Hyperbilirubinemia | NeoReviews - AAP Publications — neoreviews.aappublications.org — https://neoreviews.aappublications.org/content/21/11/e749
22. Jaundice: Newborn to Age 2 Months | Pediatrics In Review — pedsinreview.aappublications.org — https://pedsinreview.aappublications.org/content/38/11/499
23. High‐ versus low‐dose phototherapy for neonatal jaundice - Lai, NM - 2026 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003308.pub3/related-content
24. [PDF] Phototherapy to Prevent Severe Neonatal Hyperbilirubinemia in the ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/162431/cdc_162431_DS1.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.